title: 4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
abstract: The authors report the preliminary data concerning a phase III study comparing the chemoprophylactic effects of mitomycin C and epirubicin in Ta-T1 primary and recurrent superficial bladder tumors. 60 patients were treated, 32 with epirubicin and 28 with mitomycin C, with a medium follow-up of 17.7 and 16.2 months, respectively. There were no systemic side effects. The remission rate was 62.5% in the epirubicin group and 64.2% in the mitomycin C group. Both drugs were equally useful in the chemoprophylaxis of superficial bladder cancer.
authors.affiliation: Department of Urology, Desterro Hospital, Lisbon, Portugal.
authors.forename: F C
authors.initials: FC
authors.lastname: da Silva
authors.forename: F
authors.initials: F
authors.lastname: Ferrito
authors.forename: T
authors.initials: T
authors.lastname: Brandão
authors.forename: A
authors.initials: A
authors.lastname: Santos
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D015251:Epirubicin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D015251:Epirubicin; D016685:Mitomycin